Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.40 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2827742 | 0.91 | GAA (0.50) | LMNAADORA3NPSR1PPARGNCOA2 | |
| SCHEMBL2829272 | 0.89 | KMT2A (0.52) | LMNANPSR1PPARGNCOA2GAA | |
| SCHEMBL2829309 | 0.88 | PIM1 (0.48) | LMNAKDM4ETP53MEN1KMT2A | |
| SCHEMBL2853086 | 0.88 | ALDH1A1 (0.44) | LMNAPPARGNCOA2KDM4ETP53 | |
| SCHEMBL4986783 | 0.87 | SMN1; SMN2 (0.44) | LMNAADORA3NPSR1KDM4EADORA2A | |
| SCHEMBL2829708 | 0.87 | KMT2A (0.46) | LMNAPPARGNCOA2KDM4ETP53 | |
| SCHEMBL2826616 | 0.86 | POLB (0.42) | LMNACA12CA2CA9GAA | |
| SCHEMBL2830390 | 0.86 | ALDH1A1 (0.44) | LMNAGAAKDM4ETP53POLB | |
| SCHEMBL2832702 | 0.85 | ADORA3 (0.46) | LMNAADORA3PPARGNCOA2GAA | |
| SCHEMBL2831568 | 0.85 | POLB (0.38) | LMNACA12CA2CA9ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948648-B1 | 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | claimed |
| EP-1948648-A2 | 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURAN DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-30 | — | — | EP | claimed |
| US-7388025-B2 | 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-06-17 | — | — | US | claimed |
| WO-2007054444-A2 | 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURAN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-18 | — | — | WO | claimed |
| US-20070105922-A1 | 3-aryl-isoxazole-4-carbonyl-indole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-10 | — | — | US | claimed |
| EP-1948648-B1 | 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | disclosed |
| EP-1948648-A2 | 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURAN DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-30 | — | — | EP | disclosed |
| US-7388025-B2 | 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-06-17 | — | — | US | disclosed |
| WO-2007054444-A2 | 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURAN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105922-A1 | 3-aryl-isoxazole-4-carbonyl-indole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105922-A1 | 3-aryl-isoxazole-4-carbonyl-indole derivatives | GABRA5, GABRA4, GABRA3 | LMNA 3467/4885CA12 2937/4885CA2 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.